Drug Profile
AIC 292
Alternative Names: AIC292Latest Information Update: 16 Mar 2016
Price :
$50
*
At a glance
- Originator AiCuris
- Class Antiretrovirals
- Mechanism of Action Non-nucleoside reverse transcriptase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported HIV infections
Most Recent Events
- 16 Mar 2016 No recent reports on development identified - Phase-I for HIV infections in Germany (PO)
- 01 Jul 2010 Phase-I clinical trials in HIV infections in Germany (PO)